The US neurological disorder drugs market is anticipated to grow significantly over the forecast period (2020-2026). Rising cases of neurological disorders, geriatric population, and rapid advancement by the key players operating in the neurological disorder drugs landscape are some of the key factors that drive the growth of the US neurological disorder drugs industry.
Besides, frequent developments in healthcare and drug discovery are leading to the introduction of new drugs for the treatment of neurological diseases. Key authorities such as WHO, National Institutes of Health, and National Institute of Neurological Disorders and Stroke are taking productive steps that flares-up the research activities for the novel drug discovery. For instance, in August 2019, the National Center for Advancing Translational Sciences and National Institute of Neurological Disorders and Stroke invited researchers to conduct a study on rare neurological and neuromuscular disorders.
To Request a Sample of our Report on US Neurological Disorder Drugs Market: https://www.omrglobal.com/request-sample/us-neurological-disorder-drugs-market
Besides the presence of the key players such as Eli Lilly and Co., Merck & Co. Inc., and Pfizer Inc. are contributing to the growth of the US neurological disorder drugs market growth. Further, the well-established healthcare infrastructure and a significant rise in the population with the age group ranging between 18 and 64 are also driving the market growth. For instance, as per the US Census Bureau, the total population in the US was more than 325.7 million, of which 62% was constituted by 18-64 age group people.
Market Coverage
· Market number available for – 2019-2026
· Base year- 2019
· Forecast period- 2020-2026
· Segment Covered- By Disorder Type
· Country Covered- US
· Competitive Landscape- Eli Lilly and Co., Merck & Co. Inc., Abbvie Inc., Apotex Inc., AstraZeneca Plc, Pfizer Inc., Biogen Inc., and Amgen Inc.
Key questions addressed by the report
· What is the market growth rate?
· Which segment dominates the market in the base year?
· Which segment will project the fastest growth in the market?
· How COVID-19 impacted the market?
· Recovery Timeline
· Deviation from the pre-COVID-19 forecast
· Most affected segment
· Who is the leader in the market?
· How players are addressing challenges to sustain growth?
· Where is the investment opportunity?
(Get 15% Discount on Buying this Report)
A full Report of US Neurological Disorder Drugs Market is Available at: https://www.omrglobal.com/industry-reports/us-neurological-disorder-drugs-market
US Neurological Disorder Drugs Market – Segmentation
By Disorder Type
· Alzheimer’s Disease
· Parkinson’s Disease
· Multiple Sclerosis
· Huntington Disease
· Others
(This release has been published on Global Market Post. Global Market Post is not responsible for any content included in this release.)
